# US 2026/0083924 A1 · Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083924 A1
- Document ID: US20260083924A1
- Status: Published application
- Kind: A1
- Application number: 19/112,743
- Filed: 2023-09-21
- Published: 2026-03-26
- Earliest claimed: 2022-09-22
- Assignees: Chiesi Farmaceutici S.p.A.
- Applicants: Chiesi Farmaceutici S.P.A.
- Inventors: Francesca BUTTINI; Giada VARACCA; Romina OSELLO
- Web page: https://patentgrep.com/patent/US20260083924A1

## CPC

- A61M 15/0021: {Mouthpieces therefor}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4425: Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61M 15/0035: {Piercing means}
- A61M 15/0041: {with movable piercing or cutting means}
- A61M 15/08: Inhaling devices inserted into the nose
- A61M 2202/064: Powder
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition loaded in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.

## Claims

### Claim 1

A drug product, comprising a single-dose dry powder inhalation device, comprising an inhaler body (2) defining a recess (3) for a capsule (4), wherein the capsule (4) holds herein a pharmaceutical composition to be inhaled, a nosepiece or mouthpiece (5) communicating with the recess (3), at least one rupturing element (7) coupled to the inhaler body (2) and configured for rupturing the capsule (4) to allow an outside airflow to be mixed with the pharmaceutical composition of the capsule (4) and inhaled through the nosepiece or the mouthpiece (5), and
a pharmaceutical composition filled in a capsule, the pharmaceutical composition comprising micronized particles having a size of from 0.1 to 15 microns of a compound of formula (I)
and carrier particles,
wherein the inspiratory flow rate of said inhaler is from 30 l/min to 65 l/min at 4 kPa of pressure drop, and
wherein the unitary nominal dose of the compound of formula (I) is from 450 to 600 μg.

### Claim 2 (depends on 1)

The drug product according to claim 1, wherein the unitary nominal dose is from 480 to 550 μg.

### Claim 3 (depends on 1)

The drug product according to claim 1, wherein the carrier is selected from the group consisting of a polyol, a crystalline sugar, an inorganic salt, an organic salt, an organic compound, a polysaccharide, and an oligosaccharide.

### Claim 4 (depends on 1)

The drug product according to claim 1, wherein the carrier particles comprise a mixture of particles having a size of one or a few hundred microns, and particles having a size up to a few tens of microns, and a ternary agent.

### Claim 5 (depends on 1)

The drug product according to claim 1, wherein the carrier comprises:
a) a fraction of fine particles made of a mixture comprising 90 to 99.5 percent by weight of particles of a physiologically acceptable excipient and 0.5 to 10 percent by weight of a ternary agent, said mixture having a volume median diameter lower than 20 microns; and
b) a fraction of coarse particles comprising a physiologically acceptable excipient having a volume median diameter equal to or higher than 100 microns as measured by means of laser diffraction or sieve analyzer,
wherein the ratio between the fine particles and the coarse particles is comprised between 1:99 and 30:70 percent by weight.

### Claim 6 (depends on 1)

The drug product according to claim 1, wherein the inspiratory flow rate is from 40 l/min to 65 l/min at 4 kPa of pressure drop.

### Claim 7

A method for the treatment of a respiratory disease, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising micronized particles having a size of from 0.1 to 15 microns of a compound of formula (I)
and carrier particles,
wherein said composition is administered using a single-dose dry powder inhalation device whose inspiratory flow rate is from 30 l/min to 65 l/min, and
wherein the unitary dose of the compound of formula (I) is from 450 to 600 μg.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the respiratory disease is asthma or chronic obstructive pulmonary disease.

### Claim 9 (depends on 1)

A process for the preparation of a drug product according to claim 1, said process comprising:
a) preparing microparticles comprising a mixture comprising particles made of physiologically acceptable pharmacologically-inert material and particles of an additive, the inert material and the additive being first-mixed together and then co-micronized;
b) mixing the microparticles obtained in step a) with coarse particles of a physiologically acceptable pharmacologically-inert material such that microparticles adhere to the surface of the coarse particles;
c) adding by mixing the active particles in the micronized form to the particles obtained in step b) to obtain the final pharmaceutical composition;
d) filing the obtained final pharmaceutical composition in a capsule; and
c) loading the capsule in a medicament chamber of a single dry powder inhalation device.
